Related Experiment Video
Updated: Jan 9, 2026

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
Published on: November 20, 2018
Inhibiting Disulfide Bonding in Truncated Tau297-391 Results in Enhanced Self-Assembly of Tau into Seed-Competent
Sebastian S Oakley1,2, Karen E Marshall1,2, Georg Meisl3
1Sussex Neuroscience, School of Life Sciences, University of Sussex, Falmer, East Sussex BN1 9QG, U.K.
Abstract:
Tau undergoes fibrillogenesis in a group of neurodegenerative diseases, termed tauopathies. Each tauopathy is characterized by tau fibrils with disease-specific conformations, highlighting the complexity of tau self-assembly. This has led to debate surrounding the precise mechanisms that govern the self-assembly of tau in disease, especially the involvement of disulfide bonding (DSB) between cysteine residues. In this study, we use a truncated form of tau, dGAE, capable of forming filaments identical to those in disease. We reveal the impact of DSB on dGAE assembly and propagation by resolving the global mechanisms that dominate its assembly. We found evidence of surface-mediated secondary nucleation and fragmentation being active in dGAE assembly. The inhibition of DSB during dGAE assembly leads to an enhanced aggregation rate through a reduced lag phase but with no effect on the global assembly mechanisms. We suggest this is due to the formation of a dominant, seed-competent species in the absence of DSB that facilitates elongation and secondary nucleation, resulting in enhanced assembly. In vitro seeding assays reveal the recruitment of endogenous tau in a cell model only when using dGAE species formed under conditions that inhibit DSB. Our results further support the use of the in vitro dGAE tau aggregation model for investigating the mechanism of tau assembly, show the effect of varying conditions on tau assembly, and how these conditions affect the resultant species. Further studies may utilize dGAE and its aggregates to investigate tau seeding, propagation, and to highlight or test potential targets for therapies that reduce the spread of pathological tau throughout the brain.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Protein Folding
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Drugs that Stabilize Microtubules

